THESE ARTICLES ARE COPYRIGHTED BY THE PUBLISHER

UNAUTHORIZED COPYING AND DISTRIBUTION IS PROHIBITED

Publications and Communications

Peer-reviewed articles

1. Griebel G, Saffroy Spittler M, Misslin R, Vogel E, Martin JR (1990) Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice. Psychopharmacology 102: 498-502. Pdf

2. Misslin R, Griebel G, Saffroy Spittler M, Vogel E (1990) Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. NeuroReport 1: 267-270. Pdf

3. Griebel G, Saffroy Spittler M, Misslin R, Remmy D, Vogel E, Bourguignon JJ (1991) Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX. Psychopharmacology 103: 541-544. Pdf

4. Griebel G, Misslin R, Vogel E, Bourguignon JJ (1991) Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors. Pharmacology Biochemistry and Behavior 39: 321-323. Pdf

5. Griebel G, Misslin R, Vogel E (1991) Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice. NeuroReport 2: 139-140. Pdf

6. Griebel G, Misslin R, Pawlowski M, Vogel E (1991) m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. NeuroReport 2: 627-629. Pdf

7. Bouchon R, Griebel G, Vogel E, Misslin R, Ropartz P (1992) Prolactin similar to ectopic pituitary isograft restores responsiveness in Snell dwarf mice. NeuroReport 3: 210-212. Pdf

8. Griebel G, Misslin R, Pawlowski M, Guardiola Lemaitre B, Guillaumet G, Bizot Espiard J (1992) Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice. NeuroReport 3: 84-86. Pdf

9. Moreau JL, Griebel G, Jenck F, Martin JR, Widmer U, Haefely WE (1992) Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys. Brain Research Bulletin 29: 901-904. Pdf

10. Griebel G, Belzung C, Misslin R, Vogel E (1993) The free-exploratory paradigm: An effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behavioural Pharmacology 4: 637-644. Pdf

11. Griebel G, Moreau J-L, Jenck F, Martin JR, Misslin R (1993) Some critical determinants of the behaviour of rats in the elevated plus-maze. Behavioural Processes 29: 37-47. Pdf

12. Griebel G, Moreau J-L, Jenck F, Misslin R, Martin JR (1994) Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113: 463-470. Pdf

13. Griebel G, Moreau JL, Jenck F, Mutel V, Martin JR, Misslin R (1994) Evidence that tolerance to the anxiogenic-like effects of mCPP does not involve alteration in the function of 5-HT2C receptors in the rat choroid plexus. Behavioural Pharmacology 5: 642-645. Pdf

14. Blanchard DC, Griebel G, Blanchard RJ (1995) Gender bias in the preclinical psychopharmacology of anxiety: Male models for (predominantly) female disorders. Journal of Psychopharmacology 9: 79-82. Pdf

15. Griebel G, Blanchard DC, Jung A, Lee JC, Masuda CK, Blanchard RJ (1995) Further evidence that the Mouse Defense Test Battery is useful for screening anxiolytic and panicolytic drugs: Effects of acute and chronic treatment with alprazolam. Neuropharmacology 34: 1625-1633. Pdf

16. Griebel G, Blanchard DC, Jung A, Blanchard RJ (1995) A model of 'antipredator' defense in Swiss-Webster mice: Effects of benzodiazepine receptor ligands with different intrinsic activities. Behavioural Pharmacology 6: 732-745. Pdf

17. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995) Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120: 57-66. Pdf

18. Griebel G, Blanchard DC, Jung A, Masuda CK, Blanchard RJ (1995) 5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone. Pharmacology Biochemistry and Behavior 51: 235-244. Pdf

19. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmacology and Therapeutics 65: 319-395. Pdf

20. Griebel G, Sanger DJ, Perrault G (1996) The Mouse Defense Test Battery: Evaluation of the effects of non-selective and BZ-1 (w 1) selective, benzodiazepine receptor ligands. Behavioural Pharmacology 7: 560-572. Pdf

21. Griebel G, Sanger DJ, Perrault G (1996) The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (w 1) selective, benzodiazepine receptor ligands. Psychopharmacology 124: 245-254. Pdf

22. Griebel G, Blanchard DC, Blanchard RJ (1996) Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: A factor analytic study. Physiology and Behavior 60: 1255-1260. Pdf

23. Griebel G, Blanchard DC, Blanchard RJ (1996) Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. Progress in Neuro-Psychopharmacology and Biological Psychiatry 20: 185-205. Pdf

24. Griebel G, Blanchard DC, Rettori MC, Guardiola-Lemaître B, Blanchard RJ (1996) Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S21357. Pharmacology Biochemistry and Behavior 54: 509-516. Pdf

25. Griebel G, Sanger DJ, Perrault G (1996) Further evidence for differences between non-selective and BZ-1 (w 1) selective, benzodiazepine receptor ligands in murine models of ''state'' and ''trait'' anxiety. Neuropharmacology 35: 1081-1091. Pdf

26. Griebel G (1996) Variability in the effects of 5-HT-related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story? Polish Journal of Pharmacology 48: 129-136. Pdf

27. Blanchard RJ, Griebel G, Guardiola-Lemaître B, Brush MM, Lee J, Blanchard DC (1997) An ethopharmacological analysis of selective activation of 5-HT1A receptors: The mouse 5-HT1A syndrome. Pharmacology Biochemistry and Behavior 57: 897-908. Pdf

28. Blanchard RJ, Griebel G, Henrie JA, Blanchard DC (1997) Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neuroscience and Biobehavioral Reviews 21: 783-789. Pdf

29. Griebel G, Sanger DJ, Perrault G (1997) Genetic differences in the mouse defense test battery. Aggressive Behaviors 23: 19-31. Pdf

30. Griebel G, Perrault G, Sanger DJ (1997) A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36: 793-802. Pdf

31. Griebel G, Perrault G, Sanger DJ (1997) Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology 131: 180-186. Pdf

32. Griebel G (1997) Serotonergic drugs in animal models of anxiety: an update. Serotonin ID research alert 2: 251-257. Pdf

33. Griebel G, Perrault G, Sanger DJ (1997) CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behavioural Pharmacology 8: 549-560. Pdf

34. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (1997) Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacology Biochemistry and Behavior 57: 817-827. Pdf

35. Blanchard DC, Griebel G, Rodgers RJ, Blanchard RJ (1998) Benzodiazepine and serotonergic modulation of antipredator and conspecific defense. Neuroscience and Biobehavioral Reviews 22: 597-612. Pdf

36. Griebel G, Perrault G, Sanger DJ (1998) Characterization of the behavioral profile of the non peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents - Comparison with diazepam and buspirone. Psychopharmacology 138: 55-66. Pdf

37. Griebel G, Curet O, Perrault G, Sanger DJ (1998) Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology 37: 927-935. Pdf

38. Griebel G, Perrault G, Sanger DJ (1998) Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. Journal of Psychopharmacology 12: 356-365. Pdf

39. Griebel G, Perrault G, Sanger DJ (1999) Study of the modulatory activity of BZ (w ) receptor ligands on defensive behaviors in mice: Evaluation of the importance of intrinsic efficacy and receptor subtype selectivity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 23: 81-98. Pdf

40. Griebel G, Perrault G, Sanger DJ (1999) Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (w ) receptor agonists on defensive behaviors of mice. Pharmacology Biochemistry and Behavior 62: 689-694. Pdf

41. Griebel G (1999) Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacology and Therapeutics 82: 1-61. Pdf

42. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (1999) Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT1A receptor antagonists. Psychopharmacology 144: 121-130. Pdf

43. Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ (1999) Pharmacological studies on synthetic flavonoids: comparison with diazepam. Neuropharmacology 38: 965-977. Pdf

44. Griebel G, Perrault G, Sanger DJ (1999) Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Research 836: 221-224. Pdf

45. Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ (1999) Comparison of the pharmacological properties of classical and novel BZ-w receptor ligands. Behavioural Pharmacology 10: 483-495. Pdf

46. Griebel G, Cohen C, Perrault G, Sanger DJ (1999) Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. Physiology and Behavior 67: 315-320. Pdf

47. Sanger DJ, Griebel G, Perrault G, Claustre Y, Schoemaker H (1999) Discriminative stimulus effects of drugs acting at GABAA receptors: Differential profiles and receptor selectivity. Pharmacology Biochemistry and Behavior 64: 269-273. Pdf

48. Griebel G, Perrault G, Letang V, Granger P, Avenet P, Schoemaker H, Sanger DJ (1999) New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (w) receptor subtypes. Psychopharmacology 146: 205-213. Pdf

49. Griebel G (1999) 5-HT1A receptor blockers as potential drug candidates for the treatment of anxiety disorders. Drug News & Perspectives 12: 484-490. Pdf

50. Griebel G, Belzung C, Perrault G, Sanger DJ (2000) Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 148: 164-170. Pdf

51. Belzung C, Le Guisquet AM, Griebel G (2000) b-CCT, a selective BZ-w1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. Behavioural Pharmacology 11:125-131. Pdf

52. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (2000) The effects of compounds varying in selectivity as 5-HT1A receptor antagonists in three rat models of anxiety. Neuropharmacology 39:1848-1857. Pdf

53. Andreatini R., Blanchard C., Blanchard R., Brandão M.L., Carobrez A.P., Griebel G., Guimarães F.S., Handley S.L., Jenck F., Leite J.R., Rodgers J., Schenberg L.C., Da Cunha C. and Graeff F.G. (2001) The brain decade in debate: II. Panic or anxiety? From animal models to a neurobiological basis. Brazilian Journal of Medical and Biological Research 34:145-154. Pdf

54. Blanchard D.C., Griebel G. and Blanchard R.J. (2001) Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neuroscience Biobehavioral Reviews 25:205-218. Pdf

55. Griebel G., Perrault G., Simiand J., Cohen C., Granger P., Decobert M., Françon D., Avenet P., Depoortere H., Tan S., Oblin A., Schoemaker H., Evanno Y., Sevrin M., George P., Scatton S. (2001) SL651498: an anxioselective compound with functional selectivity for a2- and a3-containing GABAA receptors. Journal of Pharmacological and Experimental Therapeutics 298:753-768. Pdf

56. Belzung C., El Hage W., Moindrot N. and Griebel G. (2001) Behavioral and neurochemical changes following predatory stress in mice : strain comparison and effects of anxiolytic drug treatments. Neuropharmacology 41:400-408. Pdf

57. Steinberg R., Alonso R., Griebel G., Bert L., Jung M., Oury-Donat F., Poncelet M., Gueudet C., Desvignes C., Le Fur G. and Soubrié P. (2001) Selective blockade of neurokinin NK2 receptors produces antidepressant-like effects associated with reduced CRF function. Journal of Pharmacological and Experimental Therapeutics 299:449-458. Pdf

58. Belzung C. and Griebel G. (2001) Measuring normal and pathological anxiety in mice: a review. Behavioural Brain Research 125:141-149. Pdf

59. Griebel G., Perrault G. and Soubrié P. (2001) Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology 158:241-251. Pdf

60. Griebel G., Moindrot N., Aliaga C., Simiand J. and Soubrié P. (2001) Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neuroscience and Biobehavioral Reviews 25:619-626. Pdf

61. Serradeil-Le Gal C., Wagnon J., Simiand J., Griebel G., Lacour C., Guillon G., Barberis C., Brossard G., Soubrié P., Nisato D., Pascal M., Pruss R., Scatton B., Maffrand J.-P. and Le Fur G. (2002) Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist. Journal of Pharmacological and Experimental Therapeutics 300:1122-1130. Pdf

62. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.-P. and Soubrié P. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. II. Characterization in Rodent Models of Stress-Related Disorders. Journal of Pharmacological and Experimental Therapeutics 301:333-345. Pdf

63. Gully D., Geslin M., Serva L., Fontaine E., Roger P., Lair C., Darre V., Marcy C., Rouby P.-E., Simiand J., Guitard J., Gout G., Steinberg R., Rodier D., Griebel G., Soubrié P., Pascal M., Pruss R., Maffrand J.-P. and Le Fur G. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. I. Biochemical and Pharmacological Characterization. Journal of Pharmacological and Experimental Therapeutics 301:322-332. Pdf

64. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., Maffrand J.-P. and Soubrié P. (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proceedings of the National Academy of Sciences of the United States of America 99: 6370-6375. Pdf - Press Releases

65. Steinberg R., Alonso R., Rouquier L., Desvignes C., Michaud J.-C., Cudennec A., Jung M., Simiand J., Griebel G., Emonds-Alt X., Le Fur G. and Soubrié P. (2002) SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichloro phenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. The Journal of Pharmacology and Experimental Therapeutics 303:1180-1188. Pdf

66. Griebel G., Perrault G., Simiand J., Cohen C., Granger P., Depoortere H., Françon D., Avenet P., Schoemaker H., Evanno Y., Sevrin M., George P. and Scatton B. (2003) SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Reviews 9:3-20. Pdf

67. Blanchard D.C., Griebel G. and Blanchard R.J. (2003) The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. European Journal of Pharmacology 463: 97-116. Pdf

68. Ducottet C., Griebel G. and Belzung C. (2003) Effects of the selective non-peptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27:625-631. Pdf

69. Griebel G., Simiand J., Stemmelin J., Serradeil-Le Gal C. and Steinberg R. (2003) The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Current Drug Targets – CNS & Neurological Disorders 2:191-200. Pdf

70. Holmes A., Heilig M., Rupniak N.M.J., Steckler T. and Griebel G. (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences 24:580-588. Pdf

71. Blanchard D.C., Griebel G. and Blanchard R.J. (2003) Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27:1177-1185. Pdf

72. El Hage W., Peronny S., Griebel G. and Belzung C. (2004) Impaired memory following predatory stress in mice is improved by fluoxetine. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28:123-128. Pdf

73. Farrokhi C., Blanchard D.C., Griebel G., Yang M., Gonzalez C., Markham C. and Blanchard R.J. (2004) Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters. Pharmacology Biochemistry & Behavior 77:465-469. Pdf

74. Alonso R., Griebel G., Pavone G., Stemmelin J., Le Fur G. and Soubrié P (2004). Blockade of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Molecular Psychiatry 9:278-286. Pdf

75. Griebel G., Simiand J., Stemmelin J., Serradeil-Le Gal C., Wagnon J., Steinberg R. and Soubrié P. (2004) Anxiolytic- and antidepressant-like effects of non-peptide vasopressin V1b receptor antagonists. Actualités de Chimie Thérapeutique 30:37-53. Pdf

76. Holmes A., Griebel G., Heilig M. and Steckler T. (2004) Response to Roesler et al.: Neuropeptides and stress-related disorders – multiple targets and converging concepts. Trends in Pharmacological Sciences 25:242-243. Pdf

77. Boulay D., Depoortère R., Louis C., Perrault G., Griebel G. and Soubrié P. (2004) SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phenyclidine. Neuropharmacology 46:1121-1129. Pdf

78. Overstreet D.H. and Griebel G. (2004) Antidepressant-like effects of the CRF1 antagonist SSR125543 in an animal model of depression. European Journal of Pharmacology 497:49-53. Pdf

79. Serradeil-Le Gal C., Derick S., Brossard G., Manning M., Simiand J., Gaillard R., Griebel G. and Guillon G. (2004) Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. Stress 6:199-206. Pdf

80. Cohen C., Perrault G., Griebel G. and Soubrié P. (2005) Nicotine-associated environmental stimuli maintain nicotine-seeking behaviour in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30:145-155. Pdf

81. Stemmelin J., Lukovic L., Salomé N. and Griebel G. (2005) Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 30:35-42. Pdf

82. Blanchard R.J., Griebel G., Farrokhi C., Markham C.M., Yang M. and Blanchard D.C. (2005) AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters. Pharmacology Biochemistry & Behavior 80:189-194. Pdf

83. Griebel G., Stemmelin J. and Scatton B. (2005) Effects of the cannabinoid CB1 receptor antagonist, rimonabant, in models measuring different aspects of emotional reactivity in rodents. Biological Psychiatry 57:261-267. Pdf

84. Serradeil-Le Gal C., Wagnon J., Tonnerre B., Roux R., Garcia G., Griebel G. and Aulombard A. (2005) An overview of SSR149415, a selective nonpeptide vasopressin V1b receptor antagonist for the treatment of stress-related disorders. CNS Drug Reviews 11:53-68. Pdf

85. Licata S.C., Platt D.M., Cook J.M., Sarma P.V.V.S, Griebel G. and Rowlett J.K. (2005) Contribution of GABAA Receptor Subtypes to the Anxiolytic-Like, Motor, and Discriminative Stimulus Effects of Benzodiazepines: Studies with the Functionally Selective Ligand SL651498 [6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]. Journal of Pharmacological and Experimental Therapeutics 313:1118–1125. Pdf

86. Griebel G., Stemmelin J., Serradeil-Le Gal C. and Soubrié P. (2005) Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders. Current Pharmaceutical Design 11:1549-1559. Pdf

87. Cohen C., Kodas E. and Griebel G. (2005) CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacology Biochemistry & Behavior 81:387-395. Pdf

88. Overstreet D.H. and Griebel G. (2005) Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacology Biochemistry & Behavior 82:223-227. Pdf

89. Terranova J.P., Chabot C., Barnouin M.C., Perrault G., Depoortere R., Griebel G. and Scatton B. (2005) SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology 181: 134–144. Pdf

90. Egashira N., Tanoue A., Higashihara F., Fuchigami H., Sano K., Mishima K., Fukue Y., Nagai H., Takano Y., Tsujimoto G., Stemmelin J., Griebel G., Iwasaki K., Ikeda T., Nishimura R. and Fujiwara M. (2005) Disruption of the Prepulse Inhibition of the Startle Reflex in Vasopressin V1b Receptor Knockout Mice: Reversal by Antipsychotic Drugs. Neuropsychopharmacology 30:1996–2005. Pdf

91. Depoortère R. Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J.P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vigé X., Biton B., Steinberg R., Françon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrié P. and Scatton B. (2005) Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic. Neuropsychopharmacology 30:1963–1985. Pdf

92. El Hage W., Griebel G. and Belzung C. (2006) Long-term impaired memory following predatory stress in mice. Physiology & Behavior 87:45-50. Pdf

93. Belzung C.,Yalcin I., Griebel G., Surget A. and Leman S. (2006) Neuropeptides in psychiatric diseases: An overview with a particular focus on depression and anxiety disorders. CNS & Neurological Disorders - Drug Targets 5:135-145. Pdf - Editorial

94. Salomé N., Stemmelin J., Cohen C. and Griebel G. (2006)  Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacology Biochemistry & Behavior 83:533-539. Pdf

95. Salomé N., Stemmelin J., Cohen C. and Griebel G. (2006) Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology 187:237–244. Pdf

96. Louis C., Cohen C., Depoortère R. and Griebel G. (2006) Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat. Neuropsychopharmacology 31:2180–2187. Pdf

97. Biton B., Bergis O.E., Galli F., Nedelec A., Lochead A.W., Jegham S., Godet D., Lanneau C., Santamaria R., Chesney F., Léonardon J., Granger P., Debono M.W., Bohme G.A., Sgard F., Besnard F., Graham D., Coste A., Oblin A., Curet O., Vigé X., Voltz C., Rouquier L., Souilhac J., Santucci V., Gueudet C., Françon D., Steinberg R., Griebel G., Oury-Donat F., George P., Avenet P. and Scatton B. (2007) SSR180711 : a novel selective α7 nicotinic receptor partial agonist: (I) Binding and functional profile. Neuropsychopharmacology 32:1-16. Pdf

98. Pichat P., Bergis O.E., Terranova J.P., A. Urani, Duarte C., Santucci V., Gueudet C., Voltz C., Steinberg R., Stemmelin J., Oury-Donat F., Avenet F., Griebel G. and Scatton B. (2007) SSR180711A, a novel selective α7 nicotinic receptor partial agonist: (II) Efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34. Pdf

99. Kodas E., Cohen C., Louis C. and Griebel G. (2007) Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology 194:161-171. Pdf

100. Stemmelin J., Cohen C., Terranova J.P., Lopez-Grancha M., Pichat P., Bergis O., Decobert M., Santucci V., Alonso R., Stahl S.M., Keane P., Avenet P., Scatton B., Le Fur G. and Griebel G. (2008) Stimulation of the β3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33:574-587. Pdf

101. Louis C., Stemmelin J., Boulay D., Bergis O., Cohen C. and Griebel G. (2008) Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacology Biochemistry & Behavior  89:36-45. Pdf

102. Overstreet D.H., Stemmelin J. and Griebel G. (2008) Confirmation of antidepressant potential of the selective β3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology Biochemistry & Behavior 89:623-626. Pdf

103. Surget A., Saxe M., Leman S., Ibarguen-Vargas Y., Chalon S., Griebel G., Hen R. and Belzung C. (2008) Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biological Psychiatry 64:293–301. Pdf

104. Boulay D., Pichat P., Dargazanli G., Estenne-Bouhtou G., Terranova J.P., Rogacki N., Louis C., Stemmelin J., Coste A., Lanneau C., Desvignes C., Cohen C., Alonso R., Vigé X., Biton B., Steinberg R., Sevrin M., Oury-Donat F., George P., Bergis O.,  Griebel G., Avenet P. and Scatton B. (2008) Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacology Biochemistry & Behavior  91:47-58. Pdf

105. Black M.D., Varty G.B., Arad M., Barak S., De Levie A., Griebel G. and Weiner I. (2009) Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202:385–396. Pdf

106. Surget A., Wang Y., Leman S., Ibarguen-Vargas Y., Edgar N., Griebel G., Belzung C. and Sibille E. (2009) Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 34:1363-1380. Pdf

107. Barak S., Arad M., De Levie A., Black M.D., Griebel G. and Weiner I. (2009) Pro-cognitive and antipsychotic efficacy of the α7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology 34:1753–1763. Pdf

108. Boulay D., Bergis O., Avenet P. and Griebel G. (2010) The glycine transporter-1 Inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 35:416–427. Pdf

109. Overstreet D.H., Naimoli V.M. and Griebel G. (2010) Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Pharmacology Biochemistry & Behavior 96:206-210. Pdf

110. Borelli K.G., Defensor E.B., Blanchard D.C., Blanchard R.J. and Griebel G. (2010) Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery. Neuroscience Letters 485:241–245. Pdf

111. Boulay D., Depoortere R., Louis C., Lacave M., Lucas M.T. and Griebel G. (2010) SSR181507, a dopamine D2 receptor and 5-HT1A receptor ligand: Evidence for mixed anxiolytic- and antidepressant-like activities. Pharmacology Biochemistry & Behavior 97:428-435. Pdf

112. Blanchard D.C., Griebel G., Pobbe R. and Blanchard R.J. (2011) Risk assessment as an evolved threat detection and analysis process. Neuroscience Biobehavioral Reviews 35:991-998. Pdf

113. Rogacki N., Lopez-Grancha M., Naimoli V., Potestio L., Stevens R.J., Pichat P., Bergis O.E., Cohen C., Varty G.B. and Griebel G. (2011) The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition. Pharmacology Biochemistry & Behavior 98:405-411. Pdf

114. Urani A., Philbert J., Cohen C. and Griebel G. (2011) The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice. Pharmacology Biochemistry & Behavior 98:425-431. Pdf

115. Philbert J., Pichat P., Beeské S., Decobert M., Belzung C. and Griebel G. (2011) Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: A mouse model of post-traumatic stress disorder (PTSD). Behavioural Brain Research 221:149-154. Pdf

116. Black M.D, Stevens R.J., Rogacki N., Featherstone R.E., Senyah Y., Stemmelin J., Pichat P., Arad M., Barak S., De Levie A., Weiner I., Griebel G. and Varty G.B. (2011) AVE1625, a Cannabinoid CB1 Receptor Antagonist, as a Co-Treatment with Antipsychotics for Schizophrenia: Improvement in Cognitive Function and Reduction of Antipsychotic-Side Effects in Rodents. Psychopharmacology 215:149-163. Pdf

117. Surget A., Tanti A., Leonardo E.D, Laugeray A., Rainer Q., Touma C., Palme R., Griebel G., Ibarguen-Vargas Y., Hen R. and Belzung C. (2011) Antidepressants recruit new neurons to improve stress response regulation. Molecular Psychiatry 16:1177-118. Pdf

118. Griebel G. and Beeské S. (2012) Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Pharmacology & Therapeutics 133:116-123. Pdf

119. Griebel G., Pichat P., Pruniaux M.P., Beeské S., Lopez-Grancha M., Genet E., Terranova J.P, Castro A., Sánchez J.A., Black M., Varty G.B., Weiner I., Arad M., Barak S., De Levie A. and Guillot E. (2012) SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents. Pharmacology, Biochemistry & Behavior 102:203-214. Pdf

120. Griebel G., Decobert M., Jacquet A. and Beeské S. (2012) Awakening properties of newly discovered highly selective H3 receptor antagonists in rats. Behavioural Brain Research 232:416-420. Pdf

121. Griebel G. and Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? (2012) Nature Reviews Drug Discovery 11:462-478. Pdf

122. Philbert J., Pichat P., Belzung C. and Griebel G. (2012) The CRF1 receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the HPA axis. Pharmacology Biochemistry & Behavior 102:415-422. Pdf

123. Dournes C., Beeské S., Belzung C. and Griebel G. (2013) Deep brain stimulation in treatment-resistant depression in mice: Comparison with the CRF1 antagonist, SSR125543. Progress in Neuro-Psychopharmacology & Biological Psychiatry 40:213-220. Pdf

124. Griebel G., Beeské S. and Stahl S.M. (2012) The vasopressin V1b receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. Journal of Clinical Psychiatry 73:1403-1411. Pdf

125. Griebel G., Beeské S., Jacquet A., Laufrais C., Alonso R., Decobert M., Avenet P. and Françon D. (2013) Further evidence for the sleep-promoting effects of 5-HT2A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats. Neuropharmacology 70:19-26. Pdf

126. Philbert J., Belzung C. and Griebel G. (2013) The CRF1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine. Psychopharmacology 228:97-107. Pdf

127. Griebel G. and Holmes A. (2013) 50 years of hurdles and hope in anxiolytic drug discovery. Nature Reviews Drug Discovery 12:667-687. Pdf

128. Gao Z., Hurst W.J., Czechtizky W., Francon D., Griebel G., Nagorny R., Pichat P., Schwink L., Stengelin S., Hendrix J.A. and George P.G. (2013) Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. Bioorganic & Medicinal Chemistry Letters 23:6141-6145. Pdf

129. Boulay D., Ho-Van S., Bergis O., Avenet P. and Griebel G. (2013) Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia? Behavioural Pharmacology 24:543-551. Pdf

130. Douma T.N., Millan M.J., Boulay D., Griebel G., Verdouw P.M., Westphal K.G., Olivier B. and Groenink L. (2014) CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents. Psychopharmacology 231:1289-1303. Pdf

131. Griebel G., Ravinet-Trillou C., Beeské S., Avenet P. and Pichat P. (2014) Mice deficient in cryptochrome 1 (Cry1-/-) exhibit resistance to obesity induced by a high-fat diet. Frontiers in Endocrinology 5:49. Pdf

132. Belzung C., Turiault M. and Griebel G. (2014) Optogenetics to study the circuits of fear- and depression-like behaviors: A critical analysis. Pharmacology, Biochemistry & Behavior 122:144-157. Pdf

133. Philbert J., Beeské S., Belzung C. and Griebel G. (2015) The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: Comparison with paroxetine and D-cycloserine. Behavioural Brain Research 279: 41-46. Pdf

134. Griebel G., Pichat P., Beeské S., Leroy T., Redon N., Jacquet A., Françon D., Bert L., Even L., Lopez-Grancha M., Tolstykh T., Sun F., Yu Q., Brittain S., Arlt H., He T., Zhang B., Wiederschain D., Bertrand T., Houtmann J., Rak A., Vallée F., Michot N., Augé F., Menet V., Bergis O.E., George P., Avenet P., Mikol V., Didier M. and Escoubet J. (2015). Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. Scientific Reports 5:7642. Pdf

135. Koob G.F and Griebel G. (2015) Pharmacology Biochemistry and Behavior: The 2015 Transition. Pharmacology Biochemistry & Behavior 131:iii. Pdf

136. Griebel G. (2015) Neuropeptide receptor ligands for the treatment of schizophrenia: focus on neurotensin and tachykinins. Current Pharmaceutical Design 21:3807-3812. Pdf

137. Griebel G., Pichat P., Boulay D., Naimoli V., Potestio L., Featherstone R., Sahni S., Defex H., Desvignes C., Slowinski F., Vigé X., Bergis O.E., Sher R., Kosley R., Kongsamut S., Black M.D., Varty G.B. (2016) The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Scientific Reports 6:35320. Pdf

138. Griebel G. (2017) Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter. British Journal of Pharmacology 174: 2152-2153. Pdf

 

Book

1. Handbook of Anxiety And Fear. Eds Blanchard R.J, Blanchard C.B., Griebel G. and Nutt D.J. Elsevier, The Netherlands (2008). Cover - Buy

 

Book Chapters

1. Griebel G. and Sanger D.J. (1999) The Mouse Defense Test Battery: An Experimental Model of Different Emotional States. In: Animal Models of Human Emotion and Cognition. Edited by M. Haug and R.E. Whalen, American Psychological Association, Washington, DC, pp. 75-85. Pdf

2. Griebel G., Perrault G. and Sanger D.J. (2000) Subtype-selective benzodiazepine receptor ligands. In: Anxiolytics. Eds Briley M. and Nutt D. Birkhaüser Verlag, Switzerland, pp. 77-94. Pdf

3. Belzung C., Griebel G., Dubois-Carmagnat F. and Darves-Bornoz J.M. (2002) Amino acid transmitter systems. In: Biological Psychiatry. Eds D'haenen H., den Boer J.A. and Willner P. John Wiley & Sons, Ltd, pp. 915-927. Pdf

4. Blanchard D.C., Blanchard R.J. and Griebel G. (2005) Defensive Responses to Predator Threat in the Rat and Mouse. In: Current Protocols in Neuroscience. Eds Crawley J., Gerfen C., Rogawski M., Sibley D., Skolnick P. and Wray S. John Wiley & Sons, Inc., 8.19.1-8.19.20. Pdf

5. Griebel G. and Serradeil-Le Gal C. (2005) Non-peptide vasopressin V1b receptor antagonists. In: Handbook of Stress and the Brain. Part 2 Stress: Integrative and Clinical Aspects. Eds Steckler T., Kalin N.H. and Reul J.M.H.M. Elsevier, The Netherlands, pp. 409-422. Pdf

6. Belzung C., Leman S., Griebel G. (2008) Genetic factors underlying anxiety-behavior: a meta-analysis of rodent studies involving targeted mutations of neurotransmission genes. In: Handbook of Anxiety And Fear. Eds Blanchard R.J, Blanchard C.B., Griebel G. and Nutt D.J., Elsevier, The Netherlands, pp. 325-354. Pdf

7. Blanchard R.J., Blanchard D.C., Griebel G., Nutt D. (2008) Introduction to the handbook on fear and anxiety. In: Handbook of Anxiety And Fear. Eds Blanchard R.J, Blanchard C.B., Griebel G. and Nutt D.J. Elsevier, The Netherlands, pp. 3-10. Pdf

8. Turiault M., Cohen C. and Griebel G. (2010) Tachykinins. In: Encyclopedia of Psychopharmacology. Ed Stolerman I.P. Springer-Verlag, Berlin, Heidelberg, pp. 1301-1303. Pdf

9. Griebel G. and Beeské S. (2011) The Mouse Defense Test Battery: a model measuring different facets of anxiety-related behaviours. In: Mood and Anxiety Related Phenotypes in Mice: Characterization Using Behavioral Tests. Volume II. Neuromethods, vol. 63, pp. 97-106. Pdf

10. Griebel G. and Beeské S. (2014) Mood and anxiety disorders. In: In Vivo Models for Drug Discovery, First Edition. Eds Vela J.M, Maldonado R. and Hamon M. Wiley-VCH Verlag GmbH & Co. KgaA, pp. 193-205. Pdf

11. Griebel G. and Beeské S. (2014) Anxiety disorders. In: Behavioral Genetics of the Mouse: Volume II. Genetic Mouse Models of Neurobehavioral Disorders. Eds Pietropaolo S., Sluyter F. and Crusio W.E. Cambridge University Press, pp. 240-252. Pdf

Citations: 11728; h index = 61 (source Google Scholar, August 2016).

 

Oral Communications

1.     Griebel G. (1999) Traitements pharmacologiques des troubles liés au stress : point sur les approches nouvelles. Stress et Immunité: De la Clinique à la Recherche. Paris, October 5. Pdf.

 

2.     Griebel G., Perrault G., Granger P., Decobert M.,Tan S., Avenet P., Evanno Y., Sevrin M., George P., Schoemaker H., Françon D., Depoortere H., Scatton B. (2000) SL651498: a new anxiolytic with functional selectivity for GABAA2a and GABAA3a receptor subtypes. Society for Neuroscience, New Orleans, USA, November 8. Pdf

 

3.     Griebel G. (2001) Rationale for development of NK2 antagonists as anxiolytics and antidepressants. Molecules, Medicines and Mood: antidepressant development and use, BAP Midlands Regional Meeting, Birmingham, UK, March 27. Pdf

 

4.     Griebel G. (2001) Characterization of the profile of neuropeptide receptor antagonists involved in the modulation of stress response using the mouse defense test battery. IBNS Satellite Symposium on Defense, Cancun, Mexico, April 25. Pdf

 

5.     Griebel G. (2001) Brain Neurokinin-2 receptors as potential targets for anxiolytics and antidepressants. European Behavioural Pharmacology Society & European Brain and Behavior Society joint meeting, Marseille, France, September 9. Pdf

 

6.     Griebel G. (2003) The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Psychiatric Drug Discovery & Development, Princeton, USA, June 24. Pdf

 

7.     Griebel G. (2003) Anxiolytic- and antidepressant-like effects of non-peptide vasopressin V1b receptor antagonists. Second Joint French-Swiss Meeting on Medicinal Chemistry, Beaune, France, 1-4 July. Pdf

 

Posters

Kodas E., Cohen C., Louis C. and Griebel G. (2005) Rimonabant infused into the shell of the nucleus accumbens and the basolateral amygdala reduces nicotine-seeking behavior in rats. 7ème Colloque de la Société des Neurosciences, May 18-20, Lille, France. Pdf

Pichat P., Terranova J.P., Bergis O., Griebel G., Scatton B. and Le Fur G. (2005). Characterization of the cannabinoid CB1 receptor antagonist surinabant (SR147778) in models of cognition in rodents. XVth ICRS Symposium on Cannabinoids, Clearwater (Florida), June 24-27. Pdf

Boulay D., Depoortère R., Bergis O. and Griebel G. (2005) SSR240600 and saredutant, NK-1 and NK-2 receptor antagonists, respectively, increase social interaction in rats, in a model sensitive to anxiolytic drugs. Behavioural Pharmacology 16 (Supplement 1):S35. Pdf

Stemmelin J., Cohen C., Bergis O. and Griebel G. (2005) The α7nACh receptor agonist, SSR180711, displays antidepressant-like effects in rodents. Behavioural Pharmacology 16 (Supplement 1):S47. Pdf

Louis C., Cohen C. and Griebel G. (2005) Effects of three neurokinin antagonists at the NK-1, NK-2 or NK-3 receptor on the DRL 72s schedule in rats. Behavioural Pharmacology 16 (Supplement 1):S43-44. Pdf

Urani A., Bergis O. and Griebel G. (2005) SL65.0155, a 5HT4 partial agonist reverses memory deficits induced by β25-35 amyloid peptide icv administration in mice. European Neuropsychopharmacology 15 (Supplement 3): S389-390. Pdf

Stemmelin J., Cohen C., Scatton B., Le Fur G. and Griebel G. (2005) The β3 adrenoceptor agonist, SR58611A, displays anxiolytic-like effects in rodents. Program No. 109.13. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Washington, DC, USA, November 12-16. Pdf

Louis C., Terranova J.P., Decobert M., Bizot J.C., Françon D., Karson C., Alonso R., Cohen C. and Griebel G. (2005) Surinabant, a New CB1 Receptor Antagonist, Displays Efficacy in Animal Models of Attention Deficit/Hyperactivity Disorder. Neuropsychopharmacology 30 (Supplement 1): S173. ACNP 44th Annual Meeting, December 11-15, Waikoloa, Hawaii. Pdf

Culig L., Legendre S., Minier F., Griebel G., Sahay A., Hen R. and Belzung C. (2015) Effects of increasing adult hippocampal neurogenesis in mice during exposure to chronic stress. Program No. 636.02. 2015 Neuroscience Meeting Planner. Chicago: Society for Neuroscience, 2015. Online. Pdf

 

Reviewer for the following journals:

Addiction Biology

Behavioural Brain Research

Behavioural Pharmacology

Brain Research

Brazilian Journal of Medical and Biological Research

CNS Drug Reviews

CNS Spectrums

Current Drugs

European Journal of Pharmacology

Expert Opinion on Emerging Drugs

Expert Opinion on Investigational Drugs

Genes Brain & Behavior

International Journal of Neuropsychopharmacology

Journal of Neural Transmission

Journal of Neuroscience

Journal of Psychopharmacology

Life Sciences

Molecular Brain Research

Nature Protocols

Neurobiology of Learning and Memory

Neuropeptides

Neuropharmacology

Neuropsychopharmacology

Neuroscience

Neuroscience & Biobehavioral Reviews

Neuroscience Letters

Pharmacology Biochemistry & Behavior

Physiology & Behavior

PNAS

Psychobiology

Psychopharmacology

Trends in Pharmacological Sciences

European Research Council: Peer reviewer since 2013.

Editorial Acivities:

Pharmacology Biochemistry & Behavior: Editor-in-Chief (2015-); Associate Editor (2013-2014); Section Editor, Psychiatric Disorders (2010-2014); Editorial Advisory Board (2002-2010)

Faculty Member, F1000Prime, Section Pharmacology & Drug Discovery (2013-)

Current Psychiatry Reviews: Editorial Advisory Board Member (2014-)

World Journal of Psychiatry: Editorial Board (2011-)

Frontiers in Behavioral Neuroscience: Review Editor (2007-)

The Open Pharmacology Journal: Editorial Advisory Board (2007-)

 

 

Guest Editor:

 

Guest Editor: CNS & Neurological Disorders - Drug Targets, special issue on “Neuropeptide systems as novel targets for psychiatric disorders”, Volume 5, Number 2, April 2006.

 

 

Patents:

 

Drago F., Consoli D., Mazzola C., Micale V. and Griebel G. (18-04-2007) USE OF PHENYLETHANOLAMINOTETRALINES FOR PREPARING ANXIOLYTIC DRUGS. EP1773316.

 

Griebel G. and Stemmelin J. (29-03-2007) ASSOCIATION OF ss3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND THERAPEUTIC USE THEREOF. WO2007034056.

 

Sanger D.J., Griebel G. and Perrault G. (2-06-2000) AGENT FOR PROPHYLAXIS AND TREATMENT OF PANIC DISORDER. WO0030645.


Description : D:\Mes documents\Homepage\greenhomebutton.gif